Annual CFF
$595.12 M
+$281.67 M+89.86%
December 31, 2023
Summary
- As of February 26, 2025, MDGL annual cash flow from financing activities is $595.12 million, with the most recent change of +$281.67 million (+89.86%) on December 31, 2023.
- During the last 3 years, MDGL annual CFF has risen by +$590.03 million (+11596.46%).
- MDGL annual CFF is now at all-time high.
Performance
MDGL Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$7.46 M
-$126.66 M-94.44%
September 30, 2024
Summary
- As of February 26, 2025, MDGL quarterly cash flow from financing activities is $7.46 million, with the most recent change of -$126.66 million (-94.44%) on September 30, 2024.
- Over the past year, MDGL quarterly CFF has dropped by -$126.66 million (-94.44%).
- MDGL quarterly CFF is now -98.70% below its all-time high of $573.71 million, reached on March 31, 2024.
Performance
MDGL Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$1.20 B
-$12.12 M-1.00%
September 30, 2024
Summary
- As of February 26, 2025, MDGL TTM cash flow from financing activities is $1.20 billion, with the most recent change of -$12.12 million (-1.00%) on September 30, 2024.
- Over the past year, MDGL TTM CFF has dropped by -$12.12 million (-1.00%).
- MDGL TTM CFF is now -1.00% below its all-time high of $1.21 billion, reached on June 30, 2024.
Performance
MDGL TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
MDGL Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +89.9% | -94.4% | -1.0% |
| 3 y3 years | +10000.0% | -94.4% | -1.0% |
| 5 y5 years | +89.3% | -94.4% | -1.0% |
MDGL Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +247.5% | -98.7% | -100.0% | -1.0% | +1641.8% |
| 5 y | 5-year | at high | >+9999.0% | -98.7% | -100.0% | -1.0% | >+9999.0% |
| alltime | all time | at high | >+9999.0% | -98.7% | +121.2% | -1.0% | +4524.9% |
Madrigal Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $7.46 M(-94.4%) | $1.20 B(-1.0%) |
| Jun 2024 | - | $134.12 M(-76.6%) | $1.21 B(+8.2%) |
| Mar 2024 | - | $573.71 M(+19.5%) | $1.12 B(+87.5%) |
| Dec 2023 | $595.12 M(+89.9%) | $479.92 M(+2351.1%) | $595.12 M(+56.8%) |
| Sep 2023 | - | $19.58 M(-54.4%) | $379.54 M(+5.4%) |
| Jun 2023 | - | $42.93 M(-18.5%) | $359.96 M(-1.7%) |
| Mar 2023 | - | $52.69 M(-80.1%) | $366.14 M(+16.8%) |
| Dec 2022 | $313.45 M(+83.1%) | $264.34 M(>+9900.0%) | $313.45 M(+356.8%) |
| Sep 2022 | - | $0.00(-100.0%) | $68.62 M(-23.5%) |
| Jun 2022 | - | $49.11 M(>+9900.0%) | $89.72 M(-13.9%) |
| Mar 2022 | - | $0.00(-100.0%) | $104.14 M(-39.2%) |
| Dec 2021 | $171.24 M(+3265.5%) | $19.50 M(-7.6%) | $171.24 M(+9.5%) |
| Sep 2021 | - | $21.10 M(-66.8%) | $156.36 M(+15.3%) |
| Jun 2021 | - | $63.54 M(-5.3%) | $135.61 M(+87.9%) |
| Mar 2021 | - | $67.09 M(+1349.4%) | $72.18 M(+1318.7%) |
| Dec 2020 | $5.09 M(+2065.1%) | $4.63 M(+1222.6%) | $5.09 M(+1008.5%) |
| Sep 2020 | - | $350.00 K(+221.1%) | $459.00 K(+218.8%) |
| Jun 2020 | - | $109.00 K(>+9900.0%) | $144.00 K(-5.3%) |
| Mar 2020 | - | $0.00(0.0%) | $152.00 K(-35.3%) |
| Dec 2019 | $235.00 K(-99.9%) | $0.00(-100.0%) | $235.00 K(-72.2%) |
| Sep 2019 | - | $35.00 K(-70.1%) | $845.00 K(-33.0%) |
| Jun 2019 | - | $117.00 K(+41.0%) | $1.26 M(-99.6%) |
| Mar 2019 | - | $83.00 K(-86.4%) | $314.15 M(-0.1%) |
| Dec 2018 | $314.33 M(+80.9%) | $610.00 K(+35.3%) | $314.33 M(-30.0%) |
| Sep 2018 | - | $451.00 K(-99.9%) | $449.25 M(+0.1%) |
| Jun 2018 | - | $313.01 M(>+9900.0%) | $448.80 M(+163.0%) |
| Mar 2018 | - | $265.00 K(-99.8%) | $170.67 M(-1.8%) |
| Dec 2017 | $173.81 M(+1102.5%) | $135.53 M(>+9900.0%) | $173.81 M(+292.9%) |
| Sep 2017 | - | $0.00(-100.0%) | $44.23 M(-3.5%) |
| Jun 2017 | - | $34.88 M(+926.2%) | $45.86 M(+168.1%) |
| Mar 2017 | - | $3.40 M(-42.9%) | $17.10 M(+18.3%) |
| Dec 2016 | $14.45 M(+338.0%) | $5.95 M(+266.4%) | $14.45 M(+46.7%) |
| Sep 2016 | - | $1.63 M(-73.5%) | $9.85 M(-136.5%) |
| Jun 2016 | - | $6.13 M(+716.7%) | -$27.01 M(-524.6%) |
| Mar 2016 | - | $750.00 K(-44.4%) | $6.36 M(+92.8%) |
| Dec 2015 | $3.30 M | $1.35 M(-103.8%) | $3.30 M(-1019.2%) |
| Sep 2015 | - | -$35.24 M(-189.2%) | -$359.00 K(-100.6%) |
| Jun 2015 | - | $39.50 M(-1809.1%) | $60.69 M(-19.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2015 | - | -$2.31 M(+0.1%) | $75.37 M(-11.6%) |
| Dec 2014 | $85.30 M(+23.5%) | -$2.31 M(-108.9%) | $85.30 M(-41.0%) |
| Sep 2014 | - | $25.82 M(-52.3%) | $144.46 M(+22.0%) |
| Jun 2014 | - | $54.17 M(+611.2%) | $118.43 M(+84.0%) |
| Mar 2014 | - | $7.62 M(-86.6%) | $64.38 M(-6.8%) |
| Dec 2013 | $69.04 M(-40.2%) | $56.85 M(<-9900.0%) | $69.04 M(-1.7%) |
| Sep 2013 | - | -$211.00 K(-275.8%) | $70.26 M(-25.6%) |
| Jun 2013 | - | $120.00 K(-99.0%) | $94.42 M(-0.3%) |
| Mar 2013 | - | $12.28 M(-78.9%) | $94.75 M(-18.0%) |
| Dec 2012 | $115.52 M(+214.4%) | $58.07 M(+142.5%) | $115.52 M(+101.3%) |
| Sep 2012 | - | $23.95 M(+5331.1%) | $57.37 M(+72.4%) |
| Jun 2012 | - | $441.00 K(-98.7%) | $33.29 M(-50.8%) |
| Mar 2012 | - | $33.05 M(<-9900.0%) | $67.68 M(+84.2%) |
| Dec 2011 | $36.74 M(-18.6%) | -$69.00 K(-48.9%) | $36.74 M(-12.3%) |
| Sep 2011 | - | -$135.00 K(-100.4%) | $41.90 M(-25.2%) |
| Jun 2011 | - | $34.84 M(+1556.5%) | $55.99 M(+167.8%) |
| Mar 2011 | - | $2.10 M(-58.7%) | $20.91 M(-53.7%) |
| Dec 2010 | $45.16 M(-2221.0%) | $5.10 M(-63.5%) | $45.16 M(+13.8%) |
| Sep 2010 | - | $13.96 M(-5750.2%) | $39.68 M(+57.3%) |
| Jun 2010 | - | -$247.00 K(-100.9%) | $25.22 M(+1.4%) |
| Mar 2010 | - | $26.35 M(-6980.2%) | $24.87 M(-1268.2%) |
| Dec 2009 | -$2.13 M(+11.7%) | -$383.00 K(-24.2%) | -$2.13 M(-11.3%) |
| Sep 2009 | - | -$505.00 K(-14.6%) | -$2.40 M(-7.7%) |
| Jun 2009 | - | -$591.00 K(-9.1%) | -$2.60 M(+13.0%) |
| Mar 2009 | - | -$650.00 K(-0.5%) | -$2.30 M(+20.7%) |
| Dec 2008 | -$1.91 M(-104.3%) | -$653.00 K(-7.2%) | -$1.91 M(+25.2%) |
| Sep 2008 | - | -$704.00 K(+140.3%) | -$1.52 M(+62.1%) |
| Jun 2008 | - | -$293.00 K(+14.5%) | -$939.00 K(-14.5%) |
| Mar 2008 | - | -$256.00 K(-4.8%) | -$1.10 M(-102.5%) |
| Dec 2007 | $43.88 M(+11.7%) | -$269.00 K(+122.3%) | $43.88 M(-0.6%) |
| Sep 2007 | - | -$121.00 K(-73.2%) | $44.15 M(-0.3%) |
| Jun 2007 | - | -$452.00 K(-101.0%) | $44.27 M(-1.0%) |
| Mar 2007 | - | $44.73 M(-6667.5%) | $44.73 M(-6667.5%) |
| Dec 2006 | $39.29 M(+939.7%) | - | - |
| Dec 2005 | $3.78 M(-95.5%) | - | - |
| Mar 2005 | - | -$681.00 K | -$681.00 K |
| Dec 2004 | $84.28 M(+18.5%) | - | - |
| Dec 2003 | $71.12 M | - | - |
FAQ
- What is Madrigal Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals annual CFF year-on-year change?
- What is Madrigal Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals quarterly CFF year-on-year change?
- What is Madrigal Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Madrigal Pharmaceuticals?
- What is Madrigal Pharmaceuticals TTM CFF year-on-year change?
What is Madrigal Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of MDGL is $595.12 M
What is the all time high annual CFF for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high annual cash flow from financing activities is $595.12 M
What is Madrigal Pharmaceuticals annual CFF year-on-year change?
Over the past year, MDGL annual cash flow from financing activities has changed by +$281.67 M (+89.86%)
What is Madrigal Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of MDGL is $7.46 M
What is the all time high quarterly CFF for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high quarterly cash flow from financing activities is $573.71 M
What is Madrigal Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, MDGL quarterly cash flow from financing activities has changed by -$126.66 M (-94.44%)
What is Madrigal Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of MDGL is $1.20 B
What is the all time high TTM CFF for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals all-time high TTM cash flow from financing activities is $1.21 B
What is Madrigal Pharmaceuticals TTM CFF year-on-year change?
Over the past year, MDGL TTM cash flow from financing activities has changed by -$12.12 M (-1.00%)